Jennifer J. Rhodes's most recent trade in Acadia Pharmaceuticals Inc was a trade of 102,289 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on March 24, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Acadia Pharmaceuticals Inc | Jennifer J. Rhodes | EVP, CHIEF LEGAL OFFICER, SEC | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Mar 2025 | 102,289 | 102,289 | - | - | Stock Option (Right to Buy) | |
| Acadia Pharmaceuticals Inc | Jennifer J. Rhodes | EVP, CHIEF LEGAL OFFICER, SEC | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Mar 2025 | 30,062 | 30,062 | - | - | Restricted Stock Units | |
| Acadia Pharmaceuticals Inc | Jennifer J. Rhodes | EVP, CHIEF LEGAL OFFICER, SEC | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2024 | 126,589 | 126,589 | - | - | Stock Option (Right to Buy) | |
| Acadia Pharmaceuticals Inc | Jennifer J. Rhodes | EVP, CHIEF LEGAL OFFICER, SEC | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2024 | 25,889 | 25,889 | - | - | Restricted Stock Units |